Prescient Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2025: 52.86%

Prescient Therapeutics Ltd (PTX) has an Asset Resilience Ratio of 52.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$9.77 Million
≈ $6.91 Million USD Cash + Short-term Investments

Total Assets

AU$18.48 Million
≈ $13.08 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Prescient Therapeutics Ltd's Asset Resilience Ratio has changed over time. Check Prescient Therapeutics Ltd (PTX) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Prescient Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Prescient Therapeutics Ltd (PTX) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$9.75 Million 52.74%
Short-term Investments AU$20.97K 0.11%
Total Liquid Assets AU$9.77 Million 52.86%

Asset Resilience Insights

  • Very High Liquidity: Prescient Therapeutics Ltd maintains exceptional liquid asset reserves at 52.86% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Prescient Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Prescient Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%

Annual Asset Resilience Ratio for Prescient Therapeutics Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Prescient Therapeutics Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.14% AU$20.00K
≈ $14.15K
AU$14.56 Million
≈ $10.30 Million
-49.00pp
2024-06-30 49.13% AU$10.02 Million
≈ $7.09 Million
AU$20.39 Million
≈ $14.43 Million
-22.09pp
2023-06-30 71.22% AU$20.02 Million
≈ $14.17 Million
AU$28.11 Million
≈ $19.89 Million
+71.11pp
2022-06-30 0.11% AU$20.00K
≈ $14.15K
AU$17.62 Million
≈ $12.47 Million
+0.02pp
2021-06-30 0.10% AU$20.00K
≈ $14.15K
AU$20.97 Million
≈ $14.84 Million
-0.07pp
2020-06-30 0.17% AU$20.00K
≈ $14.15K
AU$12.07 Million
≈ $8.54 Million
-64.20pp
2019-06-30 64.37% AU$9.66 Million
≈ $6.83 Million
AU$15.01 Million
≈ $10.62 Million
+9.26pp
2018-06-30 55.11% AU$5.51 Million
≈ $3.90 Million
AU$9.99 Million
≈ $7.07 Million
-7.57pp
2017-06-30 62.68% AU$7.67 Million
≈ $5.42 Million
AU$12.23 Million
≈ $8.65 Million
+1.71pp
2005-06-30 60.96% AU$2.55 Million
≈ $1.80 Million
AU$4.18 Million
≈ $2.96 Million
-27.03pp
2004-06-30 87.99% AU$3.65 Million
≈ $2.58 Million
AU$4.15 Million
≈ $2.94 Million
+20.66pp
2003-06-30 67.34% AU$1.10 Million
≈ $778.32K
AU$1.63 Million
≈ $1.16 Million
-14.68pp
2002-06-30 82.02% AU$1.56 Million
≈ $1.11 Million
AU$1.90 Million
≈ $1.35 Million
-8.15pp
2001-06-30 90.16% AU$3.86 Million
≈ $2.73 Million
AU$4.28 Million
≈ $3.03 Million
--
pp = percentage points

About Prescient Therapeutics Ltd

AU:PTX Australia Biotechnology
Market Cap
$67.71 Million
AU$95.69 Million AUD
Market Cap Rank
#21414 Global
#739 in Australia
Share Price
AU$0.09
Change (1 day)
-1.09%
52-Week Range
AU$0.04 - AU$0.11
All Time High
AU$0.30
About

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more